Download PDF
Endoscopy 2015; 47(02): 136-146
DOI: 10.1055/s-0034-1390742
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts

Mohammad A. Al-Haddad
1   Department of Medicine, Indiana University, Indianapolis, Indiana, USA
,
Thomas Kowalski
2   Department of Medicine, Jefferson Digestive Disease Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
,
Ali Siddiqui
2   Department of Medicine, Jefferson Digestive Disease Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
,
Howard R. Mertz
3   Nashville GI Associates, Nashville, Tennessee, USA
,
Damien Mallat
4   Premier Gastroenterology of Texas, Dallas, Texas, USA
,
Nadim Haddad
5   Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA
,
Nidhi Malhotra
5   Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA
,
Brett Sadowski
5   Division of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA
,
Mark J. Lybik
6   Northside Gastroenterology, Indianapolis, Indiana, USA
,
Sandeep N. Patel
7   Department of Medicine, University of Texas San Antonio, San Antonio, Texas, USA
,
Emuejevoke Okoh
7   Department of Medicine, University of Texas San Antonio, San Antonio, Texas, USA
,
Laura Rosenkranz
7   Department of Medicine, University of Texas San Antonio, San Antonio, Texas, USA
,
Michael Karasik
8   Connecticut GI, Hartford, Connecticut, USA
,
Michael Golioto
8   Connecticut GI, Hartford, Connecticut, USA
,
Jeffrey Linder
9   Digestive Health Associates of Texas, Dallas, Texas, USA
,
Marc F. Catalano
10   Wisconsin Center for Advanced Research, St. Luke’s Medical Center, Milwaukee, Wisconsin, USA
› Author Affiliations
Further Information

Publication History

submitted 26 March 2014

accepted after revision 28 August 2014

Publication Date:
14 October 2014 (online)

Also available at
    Permissions and Reprints

See also:

Commentaire du travail de Al-Haddad M et al., pp. 136Endoscopy 2015; 47(02): 182-182
DOI: 10.1055/s-0034-1389863

Background and study aims: Current diagnostic testing is inadequate to determine the malignant potential of pancreatic cysts, resulting in overcautious patient management. Integrated molecular pathology (IMP) testing combines molecular analysis with first-line test results (cytology, imaging, and fluid chemistry) to assess the malignant potential of pancreatic cysts. This multicenter study aimed to determine the diagnostic accuracy of IMP for pancreatic adenocarcinoma, and the utility of IMP testing under current guideline recommendations for managing pancreatic cysts.

Patients and methods: Patients who had undergone previous IMP testing as prescribed by their physician and for whom clinical outcomes were available from retrospective record review were included (n = 492). Performance was determined by correlation between clinical outcome and previous IMP diagnosis (“benign”/“statistically indolent” vs. “statistically higher risk [SHR]”/ “aggressive”) or an International Consensus Guideline (Sendai 2012) criteria model for “surveillance” vs. “surgery.” The Cox proportional hazards model determined hazard ratios for malignancy.

Results: Benign and statistically indolent IMP diagnoses had a 97 % probability of benign follow-up for up to 7 years and 8 months from initial IMP testing. SHR and aggressive diagnoses had relative hazard ratios for malignancy of 30.8 and 76.3, respectively (both P < 0.0001). Sendai surveillance criteria had a 97 % probability of benign follow-up for up to 7 years and 8 months, but for surgical criteria the hazard ratio was only 9.0 (P < 0.0001). In patients who met Sendai surgical criteria, benign and statistically indolent IMP diagnoses had a > 93 % probability of benign follow-up, with relative hazard ratios for SHR and aggressive IMP diagnoses of 16.1 and 50.2, respectively (both P < 0.0001).

Conclusion: IMP more accurately determined the malignant potential of pancreatic cysts than a Sendai 2012 guideline management criteria model. IMP may improve patient management by justifying more relaxed observation in patients meeting Sendai surveillance criteria. IMP can more accurately differentiate between the need for surveillance or surgery in patients meeting Sendai surgical criteria.

Supplementary methods, Table e2, e3, e4 and e6, e7, e8, e9

 

  • References

  • 1 Wu BU, Sampath K, Berberian CE et al. Prediction of malignancy in cystic neoplasms of the pancreas: a population-based cohort study. Am J Gastroenterol 2014; 109: 121-129
    CrossrefPubMedGoogle Scholar
  • 2 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
    CrossrefPubMedGoogle Scholar
  • 3 Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102: 2339-2349
    Google Scholar
  • 4 Tanaka M, Fernandez-del Castillo C, Adsay V et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197
    CrossrefPubMedGoogle Scholar
  • 5 Del Chiaro M, Verbeke C, Salvia R et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis 2013; 45: 703-711
    CrossrefPubMedGoogle Scholar
  • 6 Grobmyer SR, Cance WG, Copeland EM et al. Is there an indication for initial conservative management of pancreatic cystic lesions?. J Surg Oncol 2009; 100: 372-374
    CrossrefPubMedGoogle Scholar
  • 7 Allen PJ, D’Angelica M, Gonen M et al. A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg 2006; 244: 572-582
    PubMedGoogle Scholar
  • 8 Gaujoux S, Brennan MF, Gonen M et al. Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 2011; 212: 590-600
    CrossrefPubMedGoogle Scholar
  • 9 Spinelli KS, Fromwiller TE, Daniel RA et al. Cystic pancreatic neoplasms: observe or operate. Ann Surg 2004; 239: 651-657
    CrossrefPubMedGoogle Scholar
  • 10 Huang ES, Turner BG, Fernandez-Del-Castillo C et al. Pancreatic cystic lesions: clinical predictors of malignancy in patients undergoing surgery. Aliment Pharmacol Ther 2010; 31: 285-294
    PubMedGoogle Scholar
  • 11 Esserman LJ, Thompson Jr IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013; 310: 797-798
    CrossrefPubMedGoogle Scholar
  • 12 Khalid A, McGrath KM, Zahid M et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3: 967-973
    CrossrefPubMedGoogle Scholar
  • 13 Khalid A, Zahid M, Finkelstein SD et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009; 69: 1095-1102
    CrossrefPubMedGoogle Scholar
  • 14 Shen J, Brugge WR, Dimaio CJ et al. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer 2009; 117: 217-227
    PubMedGoogle Scholar
  • 15 Matthaei H, Norris AL, Tsiatis AC et al. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012; 255: 326-333
    CrossrefPubMedGoogle Scholar
  • 16 Lee YH, Lee NJ, Kim JH et al. Sonographically guided fine needle aspiration of thyroid nodule: discrepancies between cytologic and histopathologic findings. J Clin Ultrasound 2008; 36: 6-11
    CrossrefPubMedGoogle Scholar
  • 17 Kosinski AS. A weighted generalized score statistic for comparison of predictive values of diagnostic tests. Stat Med 2013; 32: 964-977
    CrossrefPubMedGoogle Scholar
  • 18 Lawson R, Savides T, Kwong W et al. Natural history of pancreatic cystic lesions: validation of the 2012 Sendai criteria. Am J Gastroenterol 2013; 108: S91
    PubMedGoogle Scholar

    • Supplementary References

    • 1 Khalid A, Zahid M, Finkelstein SD et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009; 69: 1095-1102
      CrossrefPubMedGoogle Scholar
    • 2 Shen J, Brugge WR, Dimaio CJ et al. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer 2009; 117: 217-227
      PubMedGoogle Scholar
    • 3 Khalid A, McGrath KM, Zahid M et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005; 3: 967-973
      CrossrefPubMedGoogle Scholar
    • 4 Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007; 102: 2339-2349
      Google Scholar
    • 5 Tanaka M, Fernandez-del Castillo C, Adsay V et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197
      CrossrefPubMedGoogle Scholar
    • 6 Klöppel G, Hruban RH, Klimstra DS et al. Solid-pseudopapillary tumor of pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al, eds. World Health Organization Classification of Tumours of the Digestive System. Lyon: IARC; 2010: 327-330
      Google Scholar
    • 7 Klöppel G, Hruban R, Luttges J et al. Solid-pseudopapillary neoplasm. In: Hamilton SR, Aaltonen LA, Theise ND, , eds. World Health Organization Classification of Tumours of the Digestive System. Lyon: IARC; 2000: 246-248
      Google Scholar
    • 8 Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg 2005; 200: 965-972
      CrossrefPubMedGoogle Scholar